GLI1 and GLI2 are aberrantly activated in ccRCC and associated with poor survival of patients.
GLI1 and GLI2 are activated by the PI3K/AKT pathway via a SMO- and VHL-independent manner in ccRCC.
Simultaneously targeting GLIs and AKT pathways exhibits very potent efficacy to suppress tumor growth of ccRCC.